NEURON23 ANNOUNCES $96.5 MILLION SERIES D FINANCING AND FIRST PATIENT DOSED IN GLOBAL PHASE 2 NEULARK CLINICAL TRIAL OF NEU-411 FOR EARLY PARKINSON’S DISEASE

Reuters · 06/24 11:30

Please log in to view news